JAK inhibitor Tofacitinib citrate, Purity ≥98%

Cat. No.: X23-10-ZQ368

JAK inhibitor Tofacitinib citrate, Purity ≥98%

Synonym: Tofacitinib citrate; 540737-29-9; Tasocitinib citrate; Xeljanz; CP-690550 citrate; Tofacitinib (citrate); Tofacitinib (CP-690550) citrate; JAK inhibitor

  • MDL: MFCD11616529
  • CAS Number: 540737-29-9
  • Compound CID: 10174505
Product Size
10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
Tofacitinib citrate, soluble in warmed DMSO and insoluble in water and ethanol, is an available JAK small molecule inhibitor with potential antineoplastic activity. It targets JAK1, JAK2, AMPK, CDK2, CDK2/CyclinA, Chk1, CK2, CSK, EGFR, GSK-3β, and IRK.
Molecular Weight
504.5
Molecular Formula
C16H20N6O.C6H8O7
Targets
JAK1: 112 nM; JAK2: 20 nM; AMPK: >10 μM; CDK2: >10 μM; CDK2/CyclinA: >10 μM; Chk1: >10 μM; CK2: >10 μM; CSK: >10 μM; EGFR: >10 μM; GSK-3β: >10 μM; IRK: >10 μM
Form
Lyophilized powder
Purity
≥98%
Solubility
Warmed DMSO: 94 mg/mL (186.32 mM); Water: Insoluble; Ethanol: Insoluble
Identity
Confirmed by NMR/HPLC/MS.
Applications
Tofacitinib citrate is used in research focusing on its JAK1/3 inhibition properties for treating rheumatoid arthritis and other inflammatory diseases.
Related Products

Christmas 2024

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0